Multiple sclerosis in childhood and adolescence: clinical features and management

scientific article

Multiple sclerosis in childhood and adolescence: clinical features and management is …
instance of (P31):
review articleQ7318358
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1045364935
P356DOI10.2165/00128072-200103050-00002
P698PubMed publication ID11393326

P2093author name stringAchiron A
Sarova-Pinhas I
Pinhas-Hamiel O
P2860cites workMultiple sclerosis with early childhood onset. A case reportQ50564660
Multiple sclerosis in childhood: our experience and a review of literatureQ50866658
Lymphocyte migration and multiple sclerosis: relation with disease course and therapyQ57042653
Visual functions of optic neuritis in children caused by demyelinating diseaseQ67769763
Risk of developing multiple sclerosis after uncomplicated optic neuritis: a long-term prospective studyQ68261498
Optic neuritis in children and its relationship to multiple sclerosis: a clinical study of 21 childrenQ68466563
Multiple sclerosis in childhood: clinical profile in 125 patientsQ69228628
[Bilateral cysts of the brain, an unusual manifestation of multiple sclerosis in childhood (author's transl)]Q70654675
Multiple sclerosis in children: report of two casesQ70786752
[Two early-childhood cases of optic neuritis]Q71385681
Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment GroupQ72971445
Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study GroupQ73126318
Anti-IL-12 antibody prevents the development and progression of multiple sclerosis-like relapsing--remitting demyelinating disease in NOD mice induced with myelin oligodendrocyte glycoprotein peptideQ73336418
[Childhood multiple sclerosis and allied demyelinative diseases]Q74454499
Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosisQ74575031
Cytokine secretion of myelin basic protein reactive T cells in patients with multiple sclerosisQ77659279
Interferon beta-1b and childhood multiple sclerosisQ78068164
T cell responses to myelin basic protein in patients with spinal cord injury and multiple sclerosisQ78074655
Cellular and humoral immune responses against autoreactive T cells in multiple sclerosis patients after T cell vaccinationQ78232880
Multiple sclerosis in childhood: long term katamnestic investigationsQ93669585
What is new in the treatment of multiple sclerosis?Q30592222
Intravenous immunoglobulin therapy in multiple sclerosis: progress from remyelination in the Theiler's virus model to a randomised, double-blind, placebo-controlled clinical trialQ33596386
Recovery after optic neuritis in childhoodQ33630733
Treatment of multiple sclerosis: recent trials and future perspectivesQ33739573
New diagnostic criteria for multiple sclerosis: guidelines for research protocolsQ34271601
Risk factors for developing multiple sclerosis after childhood optic neuritisQ34446726
Interferon beta treatment for multiple sclerosis has a graduated effect on MRI enhancing lesions according to their size and pathologyQ35452670
T cell vaccination in multiple sclerosisQ36887916
Optic neuritis: prognosis for multiple sclerosis from MRI, CSF, and HLA findingsQ38338959
Optic neuritis in childhood (author's transl)Q40420639
Early onset MS under the age of 16: clinical and paraclinical featuresQ40729900
T cell response to myelin basic protein before and after treatment with interferon beta in multiple sclerosisQ40796266
Mitoxantrone immunotherapy in multiple sclerosisQ41622099
Magnetic resonance imaging of inflammatory and demyelinating white-matter diseases of childhoodQ43539539
A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study GroupQ43800957
Multiple sclerosis in childhood: Report of 15 casesQ43961828
A long perspective on childhood multiple sclerosisQ44308970
Juvenile multiple sclerosis: clinical features and prognostic characteristicsQ44464906
Multiple sclerosis in childhood: clinical features of 149 casesQ45038448
Childhood multiple sclerosis (MS): multimodal evoked potentials (EP) and magnetic resonance imaging (MRI) comparative studyQ45208638
Long-term follow-up of isolated optic neuritis: the risk of developing multiple sclerosis, its outcome, and the prognostic role of paraclinical testsQ48088205
Multiple sclerosis in children under 6 years of age.Q48135002
Multiple sclerosis beginning in infancyQ48203987
Multiple sclerosis in childhood: a new lookQ48498525
Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapsesQ48522401
Childhood multiple sclerosis treated with plasmapheresisQ48663092
Clinical aspects of multiple sclerosis in north-east Scotland with particular reference to its course and prognosisQ48842486
Multiple sclerosis in children: value of serial MR studies to monitor patientsQ48910840
P433issue5
P921main subjectmultiple sclerosisQ8277
adolescenceQ131774
P304page(s)329-336
P577publication date2001-01-01
P1433published inPediatric DrugsQ15767256
P1476titleMultiple sclerosis in childhood and adolescence: clinical features and management
P478volume3

Reverse relations

cites work (P2860)
Q44712957Bilateral uveitis intermedia. A 15-year clinical course
Q36153393Childhood-juvenile multiple sclerosis: clinical characteristics and treatment
Q33968709Cognitive dysfunction in pediatric multiple sclerosis.
Q35146006Intermediate uveitis in childhood preceding the diagnosis of multiple sclerosis: a 13-year follow-up
Q38821503Prognostic indicators in pediatric clinically isolated syndrome
Q37488902Relation between EDSS and monosymptomatic or polysymptomatic onset in clinical manifestations of multiple sclerosis in Babol, northern Iran
Q40445678Treatment of early-onset multiple sclerosis with intramuscular interferonbeta-1a: long-term results.

Search more.